%0 Journal Article
%T Segmental Erythema Multiforme-Like Drug Eruption by Aromatase Inhibitor Anastrozole ¨C First Case Report and another Example of an Immunocompromised District
%A Birgit Heinig
%A Georgi Tchernev
%A Jacqueline Sch£¿nlebe
%A Katlein Fran£¿a
%A Torello Lotti
%A Uwe Wollina
%J Archive of "Open Access Macedonian Journal of Medical Sciences".
%D 2018
%R 10.3889/oamjms.2018.026
%X Anastrozole is a non-selective aromatase inhibitor for adjuvant breast cancer therapy in postmenopausal women. Cutaneous adverse events have been reported. We observed a 64-year-old female patient with a medical history of locally advanced breast cancer of her right breast that was treated with radiotherapy and adjuvant drug therapy with anastrozole. She developed a segmental bullous eruption limited to the cancer-affected breast. Cessation of the aromatase inhibitor and systemic therapy with prednisolone cleared the lesions completely. This is the first report of a segmental erythema multiforme like drug eruption by anastrozole and another example of the concept of the immunocompromised district of skin
%K Erythema multiforme
%K Adverse skin reaction
%K Aromatase inhibitors
%K Anastrozole
%K Breast cancer
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816324/